Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • samanta
    Senior Member
    • Feb 2010
    • 108

    rambling on core facility model

    Why Core Facility Model Adopted by US Universities is a Bad Model



    Over the last decade, most chemistry and biology departments have been increasingly adopting ‘core facility’ models for acquiring latest technologies. The idea is simple. The institutes have ‘core facilities’ for providing various services to researchers working in different research areas. The core facilities are expected to run in ‘business-like’ manner, which means they are supposed to provide services at low cost and do it as ‘efficiently’ as possible.

    Few months back, we were chatting with a professor running such a facility, and when he spoke ‘business-like’, that caught our attention. We asked him several questions to figure out how the business gets run, but his numbers did not add up. For example, if we started a similar business right outside his university, we could not make it succeed. Why so? It is because he did not have to pay any rent and he did not have to worry about cost of depreciation of his instruments. Those were covered by the university. He only had to worry about hiring technicians to run the instruments/software, and deliver data to different PIs at the lowest possible cost. He explained that in exchange for free rent and machine cost, he is expected to charge lower fee to University projects than those from the outside.

    Even though the above arrangement seems like a good compromise, it is a highly inefficient and dead-end model in our opinion. The core facility is NOT a real business, because it is held hostage by the university. On the other hand, the employees of the facility are not equivalent to the professors, (who become PIs for projects), even though the professors are way behind on the technology scale compared to those working directly with instruments at core facilities. Finally, core facilities are expected to keep costs down, and therefore have very little room for trying different things (aka R&D). So, the managers of core facilities are essentially expected to run high-tech businesses, but with very limited funds for R&D.

    The failure of the model can already be seen at a higher scale. Few years back, we were talking a gentleman running a big genome sequencing center, and from his description of the operation, it seemed like he was expected (by NIH) to run the sequencing center as a giant nation-wide ‘core facility’. Essentially, he needed to focus on keeping cost/base down, and collaborate with researchers at different universities to form teams and sequence genomes. Their bioinformatics budget was limited, because NIH diktat for them was to only assemble the genome and find genes at lowest cost, and then let the community figure out the rest. He did execute his model well, but unlike real businesses like BGI, his hands were tied in many respect. For example, when Complete Genomics went down, he did not have the authority to acquire that company to expand his business reach.

    A business without reasonable control of its destiny is not a business. A research facility without power to do research is not a research facility. ‘Core facility’ fails on both aspects, and we will be surprised, if their managers do not go nuts trying to fill too many ambiguous roles.
    Last edited by samanta; 10-11-2012, 09:59 AM.
    http://homolog.us
  • westerman
    Rick Westerman
    • Jun 2008
    • 1104

    #2
    Well it is certainly a provocative title that is likely to get lots of people wandering over to your blog. I think that you are approaching the question from the wrong angle. Will write more once I find the time.

    Comment

    • samanta
      Senior Member
      • Feb 2010
      • 108

      #3
      Title? provocative content too

      Cutting and pasting here, so that members of this forum are spared from clicking another link. Primarily, we do like to hear what people here think, because they have the most direct experience to criticize our idea(s).
      Last edited by samanta; 10-11-2012, 10:01 AM.
      http://homolog.us

      Comment

      • NextGenSeq
        Senior Member
        • Apr 2009
        • 482

        #4
        Since Core Facilities can not make money they don't follow a business model. Most Institutes support Core Facilities in order to have greater control over quality and turn around time.

        Comment

        Latest Articles

        Collapse

        • mylaser
          Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by mylaser
          Kheloyar – Everything You Need to Know About Kheloyaar Login and Kheoyar Id
          If you are looking for an online gaming platform that offers a user-friendly experience, Kheloyar has become a name that many users search for. Whether you're interested in creating a new account, accessing your dashboard through Kheloyaar Login, or learning how to obtain a Kheoyar Id, understanding the platform's features and account process is essential.
          This guide explains everything you need to know about...
          Yesterday, 01:13 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 07-09-2026, 10:04 AM
        0 responses
        19 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-08-2026, 10:08 AM
        0 responses
        11 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-07-2026, 11:05 AM
        0 responses
        28 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-02-2026, 11:08 AM
        0 responses
        31 views
        0 reactions
        Last Post SEQadmin2  
        Working...